Abstract
The aim of this study is to investigate possible associations between a set of single-nucleotide polymorphisms (SNPs) within 10 genes with Schizophrenia (SCZ) and response to antipsychotics in Korean in-patients treated with antipsychotics. Two hundred and twenty-one SCZ in-patients and 170 psychiatrically healthy controls were genotyped for 42 SNPs within ABCB1, ABCB4, TAP2, CLOCK, CPLX1, CPLX2, SYN2, NRG1, 5HTR1A and GPRIN2. Baseline and final clinical measures, including the Positive and Negative Symptoms Scale (PANSS), were recorded. Rs10042486 within 5HTR1A was associated with both SCZ and clinical improvement on PANSS total scores as well as on PANSS positive and PANSS negative scores. The haplotype analyses focusing on the four, three and two blocks’ haplotypes within 5HTR1A confirmed such findings as well. We did not observe any significant association between the remaining genetic variants under investigation in this study and clinical outcomes. Our preliminary findings suggest that rs10042486 within 5HTR1A promoter region could be associated with SCZ and with clinical improvement on PANSS total, positive and negative scores in Korean patients with SCZ. However, taking into account the several limitations of our study, further research is needed to draw more definitive conclusions.
Similar content being viewed by others
References
Freedman R (2003) Schizophrenia. N Engl J Med 349:1738–1749
WHO (2001) World Health Report 2001. Mental health—new understanding—new hope. World Health Organisation, Geneva
Schlossberg K, Massler A, Zalsman G (2010) Environmental risk factors for psychopathology. Isr J Psychiatry Relat Sci 47:139–143
McGuffin P, Owen M (1991) The molecular genetics of schizophrenia: an overview and forward view. Eur Arch Psychiatry Clin Neurosci 240:169–173
McGuffin P, Owen MJ, Farmer AE (1995) Genetic basis of schizophrenia. Lancet 346:678–682
Kringlen E (2000) Twin studies in schizophrenia with special emphasis on concordance figures. Am J Med Genet 97:4–11
Ghosh A, Chakraborty K, Mattoo SK (2011) Newer molecules in the treatment of schizophrenia: a clinical update. Indian J Pharmacol 43:105–112
Norton N, Williams HJ, Owen MJ (2006) An update on the genetics of schizophrenia. Curr Opin Psychiatry 19:158–164
Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacol (Berl) 174:17–24
Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237–260
Krystal JH, D’Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacol (Berl) 169:215–233
Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrie P, Steinberg R (1998) Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32:481–488
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33 quiz 34–57
Serretti A, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Pae CU (2011) Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Res 189(1):26–32
Pae CU, Chiesa A, Mandelli L, Serretti A (2010) No influence of DTNBP1 polymorphisms on the response to aripiprazole. Neuropsychobiology 62:245–249
Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS (1990) The positive and negative syndrome Scale–Spanish adaptation. J Nerv Ment Dis 178:510–517
Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S (2007) Defining ‘response’ in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 32:1903–1910
StatSoft I (1995) STATISTICA per Windows. StatSoft Italia srl
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279–284
Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, Hillsdale
Lesch KP, Gutknecht L (2004) Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int J Neuropsychopharmacol 7:381–385
Blier P, de Montigny C (1987) Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1:470–480
Gray L, Scarr E, Dean B (2006) Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res 143:111–120
Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, Lopez JF, Watson SJ (2004) Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 55:225–233
Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, Quednow BB, Rietschel M, Wolwer W, Gaebel W, Wagner M, Maier W (2009) Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 19:91–94
Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L (2006) Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 163:1826–1829
Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamashita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A (2009) Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 150B:115–123
Fellerhoff B, Wank R (2009) Transporter associated with antigen processing and the chaperone tapasin: are non-classical HLA genes keys to the pathogenesis of schizophrenia? Med Hypotheses 72:535–538
Takao T, Tachikawa H, Kawanishi Y, Mizukami K, Asada T (2007) CLOCK gene T3111C polymorphism is associated with Japanese schizophrenics: a preliminary study. Eur Neuropsychopharmacol 17:273–276
Zhang J, Liao G, Liu C, Sun L, Liu Y, Wang Y, Jiang Z, Wang Z (2011) The association of CLOCK gene T3111C polymorphism and hPER3 gene 54-nucleotide repeat polymorphism with Chinese Han people schizophrenics. Mol Biol Rep 38:349–354
Kishi T, Kitajima T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Okumura T, Tsunoka T, Inada T, Ozaki N, Iwata N (2009) Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur Arch Psychiatry Clin Neurosci 259:293–297
Lamont EW, Coutu DL, Cermakian N, Boivin DB (2010) Circadian rhythms and clock genes in psychotic disorders. Isr J Psychiatry Relat Sci 47:27–35
Chen Q, He G, Qin W, Chen QY, Zhao XZ, Duan SW, Liu XM, Feng GY, Xu YF, St Clair D, Li M, Wang JH, Xing YL, Shi JG, He L (2004) Family-based association study of synapsin II and schizophrenia. Am J Hum Genet 75:873–877
Chen Q, He G, Wang XY, Chen QY, Liu XM, Gu ZZ, Liu J, Li KQ, Wang SJ, Zhu SM, Feng GY, He L (2004) Positive association between synapsin II and schizophrenia. Biol Psychiatry 56:177–181
Saviouk V, Moreau MP, Tereshchenko IV, Brzustowicz LM (2007) Association of synapsin 2 with schizophrenia in families of Northern European ancestry. Schizophr Res 96:100–111
Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, Evans KL, Thomson PA, Porteous DJ, Cunningham-Owens DG, Johnstone EC, Lawrie SM (2006) A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci 9:1477–1478
Mata I, Perez-Iglesias R, Roiz-Santianez R, Tordesillas-Gutierrez D, Gonzalez-Mandly A, Vazquez-Barquero JL, Crespo-Facorro B (2009) A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. Biol Psychiatry 65:535–540
Sullivan PF (2007) Spurious genetic associations. Biol Psychiatry 61:1121–1126
Zimmerman M, Mattia JI, Posternak MA (2002) Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 159:469–473
Cavalli-Sforza LL (1994) The history and geography of human genes. Princeton University Press, New Jearsey
Acknowledgments
This work was supported by the Institute of Clinical Medicine Research of Bucheon St. Mary’s Hospital, Research Fund, 2011.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Crisafulli, C., Chiesa, A., Han, C. et al. Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. Eur Arch Psychiatry Clin Neurosci 262, 199–205 (2012). https://doi.org/10.1007/s00406-011-0278-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-011-0278-3